Patents by Inventor Meaghan H. Hancock

Meaghan H. Hancock has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CMV VECTORS COMPRISING MICRORNA RECOGNITION ELEMENTS
    Publication number: 20200368333
    Abstract: Disclosed herein are recombinant CMV vectors comprising heterologous antigens and microRNA recognition elements to silence expression of CMV genes in the presence of microRNA derived from myeloid cells, an active UL128 protein and an active UL130 protein. Also disclosed are recombinant CMV vectors comprising heterologous antigens and microRNA recognition elements to silence expression of CMV genes in the presence of microRNA derived from myeloid cells, an inactive UL128 protein and an inactive UL130 protein. Also disclosed are methods of generating an unconventional immune response using these vectors. Such an immune response is characterized by generation of a CD8+ T cell response that is predominantly restricted by MHC-II.
    Type: Application
    Filed: May 8, 2020
    Publication date: November 26, 2020
    Inventors: Jay NELSON, Scott HANSEN, Meaghan H. HANCOCK, Louis PICKER, Klaus FRUEH
  • CMV vectors comprising microRNA recognition elements
    Patent number: 10688164
    Abstract: Disclosed herein are recombinant CMV vectors comprising heterologous antigens and microRNA recognition elements to silence expression of CMV genes in the presence of microRNA derived from myeloid cells, an active UL128 protein and an active UL130 protein. Also disclosed are recombinant CMV vectors comprising heterologous antigens and microRNA recognition elements to silence expression of CMV genes in the presence of microRNA derived from myeloid cells, an inactive UL128 protein and an inactive UL130 protein. Also disclosed are methods of generating an unconventional immune response using these vectors. Such an immune response is characterized by generation of a CD8+ T cell response that is predominantly restricted by MHC-II.
    Type: Grant
    Filed: November 20, 2016
    Date of Patent: June 23, 2020
    Assignee: OREGON HEALTH & SCIENCE UNIVERSITY
    Inventors: Jay Nelson, Scott Hansen, Meaghan H. Hancock, Louis Picker, Klaus Frueh
  • CMV VECTORS COMPRISING MICRORNA RECOGNITION ELEMENTS
    Publication number: 20170143809
    Abstract: Disclosed herein are recombinant CMV vectors comprising heterologous antigens and microRNA recognition elements to silence expression of CMV genes in the presence of microRNA derived from myeloid cells, an active UL128 protein and an active UL130 protein. Also disclosed are recombinant CMV vectors comprising heterologous antigens and microRNA recognition elements to silence expression of CMV genes in the presence of microRNA derived from myeloid cells, an inactive UL128 protein and an inactive UL130 protein. Also disclosed are methods of generating an unconventional immune response using these vectors. Such an immune response is characterized by generation of a CD8+ T cell response that is predominantly restricted by MHC-II.
    Type: Application
    Filed: November 20, 2016
    Publication date: May 25, 2017
    Inventors: Jay Nelson, Scott Hansen, Meaghan H. Hancock, Louis Picker, Klaus Frueh